Steven Cohen's CRDF Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 28,385 shares of Cardiff Oncology, Inc. (CRDF) worth $36,901, representing 0.00% of the portfolio. First purchased in 2021-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in CRDF for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2024, adding 508,438 shares. Largest reduction occurred in Q1 2025, reducing 508,438 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Cardiff Oncology (CRDF) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cardiff Oncology (CRDF) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +28,385 | New Buy | 28,385 | $1.30 |
| Q1 2025 | -508,438 | Sold Out | 0 | $0.00 |
| Q4 2024 | +508,438 | New Buy | 508,438 | $4.34 |
| Q1 2022 | -501,649 | Sold Out | 0 | $0.00 |
| Q4 2021 | +501,649 | New Buy | 501,649 | $6.01 |
Steven Cohen's Cardiff Oncology Investment FAQs
Steven Cohen first purchased Cardiff Oncology, Inc. (CRDF) in Q4 2021, acquiring 501,649 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Cardiff Oncology, Inc. (CRDF) for 5 quarters since Q4 2021.
Steven Cohen's largest addition to Cardiff Oncology, Inc. (CRDF) was in Q4 2024, adding 508,438 shares worth $2.21 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 28,385 shares of Cardiff Oncology, Inc. (CRDF), valued at approximately $36,901.
As of the Q2 2026 filing, Cardiff Oncology, Inc. (CRDF) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Cardiff Oncology, Inc. (CRDF) was 508,438 shares, as reported at the end of Q4 2024.